Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Afkhami

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|March 17, 2022
<i>DNMT3A</i> R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML TransformationMajd Jawad, Michelle Afkhami, Yi Ding, et al.
American Journal of Clinical Pathology|November 17, 2021
Bone Marrow Collection: Comparison of Unassisted vs Assisted Bedside Collections by a Laboratory TechnologistSaba F Ali, Adam Cloe, Parwiz J Siaghani, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
The American Journal of Surgical Pathology|February 11, 2025
Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous ComponentRachelle P Mendoza, Melisa Y Tjota, Donghyuk N Choi, et al.
International Journal of Molecular Sciences|January 25, 2025
Application of RNA-Based Next-Generation Sequencing Fusion Assay for Hematological MalignanciesFei Fei, Milhan Telatar, Vanina Tomasian, et al.
Translational Lung Cancer Research|June 15, 2026
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinomaAmanda Reyes, Isa Mambetsariev, Jeremy Fricke, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
American Journal of Hematology|February 8, 2022
High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemiaHoda Pourhassan, Dongyun Yang, Michelle Afkhami, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Journal for Immunotherapy of Cancer|July 29, 2024
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategiesAtish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|March 17, 2022
<i>DNMT3A</i> R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML TransformationMajd Jawad, Michelle Afkhami, Yi Ding, et al.
American Journal of Clinical Pathology|November 17, 2021
Bone Marrow Collection: Comparison of Unassisted vs Assisted Bedside Collections by a Laboratory TechnologistSaba F Ali, Adam Cloe, Parwiz J Siaghani, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
The American Journal of Surgical Pathology|February 11, 2025
Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas With a Mesonephric-Like Carcinomatous ComponentRachelle P Mendoza, Melisa Y Tjota, Donghyuk N Choi, et al.
International Journal of Molecular Sciences|January 25, 2025
Application of RNA-Based Next-Generation Sequencing Fusion Assay for Hematological MalignanciesFei Fei, Milhan Telatar, Vanina Tomasian, et al.
Translational Lung Cancer Research|June 15, 2026
Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinomaAmanda Reyes, Isa Mambetsariev, Jeremy Fricke, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
American Journal of Hematology|February 8, 2022
High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemiaHoda Pourhassan, Dongyun Yang, Michelle Afkhami, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Journal for Immunotherapy of Cancer|July 29, 2024
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategiesAtish Mohanty, Michelle Afkhami, Amanda Reyes, et al.
Pageof 8